New perspectives on APC control of cell fate and proliferation in colorectal cancer

Cell Cycle

Volumn 8, Issue 16, 2009, Pages 2549-2556

  Phelps, Reid A ^a,b   Broadbent, Talmage J ^a,b   Stafforini, Diana M ^a,b   Jones, David A ^a,b,c  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

APC; Colon cancer; COX 2; Differentiation; KRAS; catenin

Indexed keywords

APC; BETA CATENIN; CYCLOOXYGENASE 2 INHIBITOR; PROSTAGLANDIN E2; WNT PROTEIN;

CARCINOGENESIS; CELL DIFFERENTIATION; CELL FATE; CELL PROLIFERATION; COLON ADENOMA; COLON POLYPOSIS; COLORECTAL CANCER; DOWN REGULATION; FAMILIAL COLON POLYPOSIS; HUMAN; HUMAN CELL; INTESTINE CELL; NONHUMAN; PROTEIN FUNCTION; REVIEW;

EID: 69249222794     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.16.9278     Document Type: Review

References (94)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000; 50:7-33.
2. Havlik RJ, Yancik R, Long S, Ries L, Edwards B. The National Institute on Aging and the National Cancer Institute SEER collaborative study on comorbidity and early diagnosis of cancer in the elderly. Cancer 1994; 74:2101-2106 (Pubitemid 24304381)
3. Howe HL, Wingo PA, Thun MJ, Ries LA, Rosenberg HM, Feigal EG, et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 2001; 93:824-842
4. Myers MH, Ries LA. Cancer patient survival rates: SEER program results for 10 years of follow-up. CA Cancer J Clin 1989; 39:21-32.
5. Ries LA, Wingo PA, Miller DS, Howe HL, Weir HK, Rosenberg HM, et al. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer 2000; 88:2398-2424
6. Wingo PA, Ries LA, Giovino GA, Miller DS, Rosenberg HM, Shopland DR, et al. Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst 1999; 91:675-690
7. Spirio L, Otterud B, Stauffer D, Lynch H, Lynch P, Watson P, et al. Linkage of a variant or attenuated form of adenomatous polyposis coli to the adenomatous polyposis coli (APC) locus. Am J Hum Genet 1992; 51:92-100.
8. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87:159-170
9. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61:759-767
10. Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell 2000; 103:311-320
11. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006; 127:469-480
12. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, et al. Identification of c-MYC as a target of the APC pathway. Science 1998; 281:1509-1512 (Pubitemid 28425575)
13. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398:422-426 (Pubitemid 29180374)
14. Iwao K, Nakamori S, Kameyama M, Imaoka S, Kinoshita M, Fukui T, et al. Activation of the beta-catenin gene by interstitial deletions involving exon 3 in primary colorectal carcinomas without adenomatous polyposis coli mutations. Cancer Res 1998; 58:1021-1026 (Pubitemid 28182473)
15. Morin PJ. beta-catenin signaling and cancer. Bioessays 1999; 21:1021-1030
16. Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. Mutational analysis of the APC/betacatenin/ Tcf pathway in colorectal cancer. Cancer Res 1998; 58:1130-1134 (Pubitemid 28183198)
17. Iwao K, Nakamori S, Kameyama M, Imaoka S, Kinoshita M, Fukui T, et al. Activation of the beta-catenin gene by interstitial deletions involving exon 3 in primary colorectal carcinomas without adenomatous polyposis coli mutations. Cancer Res 1998; 58:1021-1026 (Pubitemid 28182473)
18. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275:1787-1790 (Pubitemid 27136715)
19. Romagnolo B, Berrebi D, Saadi-Keddoucci S, Porteu A, Pichard AL, Peuchmaur M, et al. Intestinal dysplasia and adenoma in transgenic mice after overexpression of an activated beta-catenin. Cancer Res 1999; 59:3875-3879 (Pubitemid 29393543)
20. Hinoi T, Akyol A, Theisen BK, Ferguson DO, Greenson JK, Williams BO, et al. Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation. Cancer Res 2007; 67:9721-9730 (Pubitemid 47621219)
21. Kongkanuntn R, Bubb VJ, Sansom OJ, Wyllie AH, Harrison DJ, Clarke AR. Dysregulated expression of beta-catenin marks early neoplastic change in Apc mutant mice, but not all lesions arising in Msh2 deficient mice. Oncogene 1999; 18:7219-7225 (Pubitemid 30032100)
22. Sansom OJ, Reed KR, Hayes AJ, Ireland H, Brinkmann H, Newton IP, et al. Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation and migration. Genes Dev 2004; 18:1385-1390 (Pubitemid 38780625)
23. Blaker H, Scholten M, Sutter C, Otto HF, Penzel R. Somatic mutations in familial adenomatous polyps. Nuclear translocation of beta-catenin requires more than biallelic APC inactivation. Am J Clin Pathol 2003; 120:418-423 (Pubitemid 37295114)
24. Anderson CB, Neufeld KL, White RL. Subcellular distribution of Wnt pathway proteins in normal and neoplastic colon. Proc Natl Acad Sci USA 2002; 99:8683-8688
25. Samowitz WS, Powers MD, Spirio LN, Nollet F, van Roy F, Slattery ML. Beta-catenin mutations are more frequent in small colorectal adenomas than in larger adenomas and invasive carcinomas. Cancer Res 1999; 59:1442-1444 (Pubitemid 29160107)
26. Kroboth K, Newton IP, Kita K, Dikovskaya D, Zumbrunn J, Waterman-Storer CM, et al. Lack of adenomatous polyposis coli protein correlates with a decrease in cell migration and overall changes in microtubule stability. Mol Biol Cell 2007; 18:910-918 (Pubitemid 46399496)
27. Penman GA, Leung L, Nathke IS. The adenomatous polyposis coli protein (APC) exists in two distinct soluble complexes with different functions. J Cell Sci 2005; 118:4741-4750 (Pubitemid 41646384)
28. Kaplan KB, Burds AA, Swedlow JR, Bekir SS, Sorger PK, Nathke IS. A role for the Adenomatous Polyposis Coli protein in chromosome segregation. Nat Cell Biol 2001; 3:429-432 (Pubitemid 32288453)
29. Yu X, Waltzer L, Bienz M. A new Drosophila APC homologue associated with adhesive zones of epithelial cells. Nat Cell Biol 1999; 1:144-151 (Pubitemid 129656018)
30. Fodde R, Smits R, Clevers H. APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer 2001; 1:55-67. (Pubitemid 33741881)
31. Hamada F, Bienz M. The APC tumor suppressor binds to C-terminal binding protein to divert nuclear beta-catenin from TCF. Dev Cell 2004; 7:677-685 (Pubitemid 39462688)
32. Nadauld LD, Phelps R, Moore BC, Eisinger A, Sandoval IT, Chidester S, et al. Adenomatous polyposis coli control of C-terminal binding protein-1 stability regulates expression of intestinal retinol dehydrogenases. J Biol Chem 2006. (Pubitemid 46042085)
33. Nadauld LD, Sandoval IT, Chidester S, Yost HJ, Jones DA. Adenomatous polyposis coli control of retinoic acid biosynthesis is critical for zebrafish intestinal development and differentiation. J Biol Chem 2004; 279:51581-51589 (Pubitemid 40017909)
34. Nadauld LD, Shelton DN, Chidester S, Yost HJ, Jones DA. The zebrafish retinol dehydrogenase, rdh1l, is essential for intestinal development and is regulated by the tumor suppressor adenomatous polyposis coli. J Biol Chem 2005; 280:30490-30495 (Pubitemid 41216233)
35. Sierra J, Yoshida T, Joazeiro CA, Jones KA. The APC tumor suppressor counteracts beta-catenin activation and H3K4 methylation at Wnt target genes. Genes Dev 2006; 20:586-600. (Pubitemid 43345324)
36. Spink KE, Polakis P, Weis WI. Structural basis of the Axin-adenomatous polyposis coli interaction. EMBO J 2000; 19:2270-2279 (Pubitemid 30259008)
37. Polakis P. Casein kinase 1: a Wnt'er of disconnect. Curr Biol 2002; 12:499-501.
38. Rosin-Arbesfeld R, Cliffe A, Brabletz T, Bienz M. Nuclear export of the APC tumour suppressor controls beta-catenin function in transcription. EMBO J 2003; 22:1101-1113 (Pubitemid 36313594)
39. Rosin-Arbesfeld R, Ihrke G, Bienz M. Actin-dependent membrane association of the APC tumour suppressor in polarized mammalian epithelial cells. EMBO J 2001; 20:5929-5939 (Pubitemid 33049268)
40. Rosin-Arbesfeld R, Townsley F, Bienz M. The APC tumour suppressor has a nuclear export function. Nature 2000; 406:1009-1012 (Pubitemid 30690468)
41. Neufeld KL, Zhang F, Cullen BR, White RL. APC-mediated downregulation of betacatenin activity involves nuclear sequestration and nuclear export. EMBO Rep 2000; 1:519-523
42. Rubinfeld B, Tice DA, Polakis P. Axin-dependent phosphorylation of the adenomatous polyposis coli protein mediated by casein kinase 1epsilon. J Biol Chem 2001; 276:39037-39045 (Pubitemid 37371271)
43. Su LK, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C, et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 1992; 256:668-670
44. Sansom OJ, Meniel V, Wilkins JA, Cole AM, Oien KA, Marsh V, et al. Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo. Proc Natl Acad Sci USA 2006; 103:14122-14127 (Pubitemid 44452990)
45. Sansom OJ, Meniel VS, Muncan V, Phesse TJ, Wilkins JA, Reed KR, et al. Myc deletion rescues Apc deficiency in the small intestine. Nature 2007; 446:676-679 (Pubitemid 46606884)
46. Sansom OJ, Reed KR, van de Wetering M, Muncan V, Winton DJ, Clevers H, et al. Cyclin D1 is not an immediate target of beta-catenin following Apc loss in the intestine. J Biol Chem 2005; 280:28463-28467 (Pubitemid 41105745)
47. Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 2008. (Pubitemid 351601205)
48. Albuquerque C, Breukel C, van der Luijt R, Fidalgo P, Lage P, Slors FJ, et al. The 'justright' signaling model: APC somatic mutations are selected based on a specific level of activation of the beta-catenin signaling cascade. Hum Mol Genet 2002; 11:1549-1560
49. Amos-Landgraf JM, Kwong LN, Kendziorski CM, Reichelderfer M, Torrealba J, Weichert J, et al. A target-selected Apc-mutant rat kindred enhances the modeling of familial human colon cancer. Proc Natl Acad Sci USA 2007; 104:4036-4041 (Pubitemid 47181574)
50. Hurlstone AF, Haramis AP, Wienholds E, Begthel H, Korving J, Van Eeden F, et al. The Wnt/beta-catenin pathway regulates cardiac valve formation. Nature 2003; 425:633-637 (Pubitemid 37280148)
51. Funayama N, Fagotto F, McCrea P, Gumbiner BM. Embryonic axis induction by the armadillo repeat domain of beta-catenin: evidence for intracellular signaling. J Cell Biol 1995; 128:959-968
52. Begemann G, Schilling TF, Rauch GJ, Geisler R, Ingham PW. The zebrafish neckless mutation reveals a requirement for raldh2 in mesodermal signals that pattern the hindbrain. Development 2001; 128:3081-3094 (Pubitemid 32825753)
53. Jette C, Peterson PW, Sandoval IT, Manos EJ, Hadley E, Ireland CM, et al. The tumor suppressor adenomatous polyposis coli and caudal related homeodomain protein regulate expression of retinol dehydrogenase L. J Biol Chem 2004; 279:34397-34405 (Pubitemid 39318065)
54. Nadauld LD, Chidester S, Shelton DN, Rai K, Broadbent T, Sandoval IT, et al. Dual roles for adenomatous polyposis coli in regulating retinoic acid biosynthesis and Wnt during ocular development. Proc Natl Acad Sci USA 2006; 103:13409-13414 (Pubitemid 44380121)
55. Hayes MA. Chronic ulcerative colitis and associated carcinoma. Am J Surg 1949; 77:363-370
56. Johnson TM, Orr TG. Carcinoma of the colon secondary to chronic ulcerative colitis. Am J Dig Dis 1948; 15:21-23
57. Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med 1992; 327:749-754
58. Miller TA. Protective effects of prostaglandins against gastric mucosal damage: current knowledge and proposed mechanisms. Am J Physiol 1983; 245:601-623
59. Soll AH, Weinstein WM, Kurata J, McCarthy D. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med 1991; 114:307-319
60. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular and molecular biology. Annu Rev Biochem 2000; 69:145-182 (Pubitemid 30792207)
61. Subbaramaiah K, Telang N, Ramonetti JT, Araki R, DeVito B, Weksler BB, et al. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res 1996; 56:4424-4429 (Pubitemid 26330450)
62. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Upregulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107:1183-1188 (Pubitemid 24294584)
63. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995; 55:2556-2559
64. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995; 55:3785-3789
65. Kutchera W, Jones DA, Matsunami N, Groden J, McIntyre TM, Zimmerman GA, et al. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci USA 1996; 93:4816-4820 (Pubitemid 26162834)
66. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325:1593-1596
67. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328:1313-1316 (Pubitemid 23131373)
68. Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991; 101:635-639
69. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993; 80:1618-1619
70. Waddell WR, Ganser GF, Cerise EJ, Loughry RW. Sulindac for polyposis of the colon. Am J Surg 1989; 157:175-179
71. Boolbol SK, Dannenberg AJ, Chadburn A, Martucci C, Guo XJ, Ramonetti JT, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996; 56:2556-2560 (Pubitemid 26171681)
72. Chiu CH, McEntee MF, Whelan J. Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis. Cancer Res 1997; 57:4267-4273 (Pubitemid 27413435)
73. Pereira MA, Barnes LH, Rassman VL, Kelloff GV, Steele VE. Use of azoxymethaneinduced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents. Carcinogenesis 1994; 15:1049-1054
74. Reddy BS, Hirose Y, Lubet R, Steele V, Kelloff G, Paulson S, et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000; 60:293-297 (Pubitemid 30070754)
75. Samaha HS, Kelloff GJ, Steele V, Rao CV, Reddy BS. Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Cancer Res 1997; 57:1301-1305 (Pubitemid 27152555)
76. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87:803-809 (Pubitemid 26404280)
77. Araki Y, Okamura S, Hussain SP, Nagashima M, He P, Shiseki M, et al. Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res 2003; 63:728-734 (Pubitemid 36158154)
78. Eisinger AL, Nadauld LD, Shelton DN, Peterson PW, Phelps RA, Chidester S, et al. The adenomatous polyposis coli tumor suppressor gene regulates expression of cyclooxygenase- 2 by a mechanism that involves retinoic acid. J Biol Chem 2006; 281:20474-20482 (Pubitemid 44065820)
79. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 2005; 310:1504-1510
80. Shao J, Jung C, Liu C, Sheng H. Prostaglandin E2 Stimulates the beta-catenin/T cell factor-dependent transcription in colon cancer. J Biol Chem 2005; 280:26565-26572 (Pubitemid 41022254)
81. Eisinger AL, Nadauld LD, Shelton DN, Prescott SM, Stafforini DM, Jones DA. Retinoic acid inhibits beta-catenin through suppression of cox-2: A role for truncated adenomatous polyposis coli. J Biol Chem 2007.
82. Kajiguchi T, Chung EJ, Lee S, Stine A, Kiyoi H, Naoe T, et al. FLT3 regulates betacatenin tyrosine phosphorylation, nuclear localization and transcriptional activity in acute myeloid leukemia cells. Leukemia 2007; 21:2476-2484 (Pubitemid 350148891)
83. Kajiguchi T, Lee S, Lee MJ, Trepel JB, Neckers L. KIT regulates tyrosine phosphorylation and nuclear localization of beta-catenin in mast cell leukemia. Leuk Res 2007. (Pubitemid 351323930)
84. Taurin S, Sandbo N, Qin Y, Browning D, Dulin NO. Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase. J Biol Chem 2006; 281:9971-9976 (Pubitemid 43864529)
85. Wu X, Tu X, Joeng KS, Hilton MJ, Williams DA, Long F. Rac1 activation controls nuclear localization of beta-catenin during canonical Wnt signaling. Cell 2008; 133:340-353
86. Phelps RA, Chidester S, Dehghanizadeh S, Phelps J, Sandoval IT, Rai K, et al. A twostep model for colon adenoma initiation and progression caused by APC loss. Cell 2009; 137:623-634
87. Kolch W. Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev 2005; 6:827-837 (Pubitemid 41568732)
88. Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 2008; 40:600-608 (Pubitemid 351601205)
89. Janssen KP, Alberici P, Fsihi H, Gaspar C, Breukel C, Franken P, et al. APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. Gastroenterology 2006; 131:1096-1109 (Pubitemid 44498698)
90. Buchanan FG, Holla V, Katkuri S, Matta P, DuBois RN. Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer. Cancer Res 2007; 67:9380-9388 (Pubitemid 47535928)
91. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005; 23:254-266 (Pubitemid 46206877)
92. Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Wissner A, et al. Combinatorial chemoprevention of intestinal neoplasia. Nature Med 2000; 6:1024-1028
93. Haramis AP, Hurlstone A, van der Velden Y, Begthel H, van den Born M, Offerhaus GJ, et al. Adenomatous polyposis coli-deficient zebrafish are susceptible to digestive tract neoplasia. EMBO Rep 2006; 7:444-449
94. Faro A, Boj SF, Ambrosio R, van den Broek O, Korving J, Clevers H. T-cell factor 4 (tcf7l2) is the main effector of Wnt signaling during zebrafish intestine organogenesis. Zebrafish 2009; 6:59-68.